Dr Reddy’s Laboratories Ltd announced the launch of Remdesivir along with its subsidiaries on Wednesday. The product is being launched under the brand name of Redyx in India.
The launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddy’s, a right to register, manufacture and sell Remdesivir, a potential treatment for COVID-19 in 127 countries, including India. Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of COVID-19 patients hospitalised with severe symptoms. Dr Reddy’s Redyx is available in the strength of 100 mg vial.
Additionally, it also announced the launch of over-the-counter (OTC) Diclofenac Sodium Topical Gel 1 per cent, the store brand version of Voltaren® Arthritis Pain in the US market.
Voltaren® is a trademark of Novartis Corporation. The company has partnered with Encube Ethicals to bring this product to market. Dr Reddy’s Diclofenac Sodium Topical Gel, 1 per cent (OTC), is used for the temporary relief of arthritis pain in certain body parts. Voltaren® Arthritis Pain brand had the total US retail sales of approximately USD 44 million since its launch in May 2020. Dr Reddy’s Diclofenac Sodium Topical Gel, 1 per cent (OTC) will soon be available in the multiple pack sizes to allow consumers, a variety of purchasing options.